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Abstract   1 
Background: 2 
Salivary gland dysfunction is one of the main clinical features of SS, manifested by 3 
xerostomia with subsequent complications and well-established effects on the 4 
person’s quality of life. 5 
Objectives:  6 
To determine firstly whether selected tests of salivary gland function and structure; 7 
unstimulated whole salivary flow rate (UWSFR), parotid flow rate (PFR), clinical oral 8 
dryness score (CODS) and ultrasound score (USS), can discriminate SS from non-9 
SS sicca patients and secondly whether these tests can differentiate between 10 
patients in different subgroups of SS.  11 
Method: 12 
UWSFR, PFR, CODS and USS were determined in 244 patients comprised of SS 13 
patients (n=118), SS patients at higher risk of lymphoma (n=30) or with lymphoma 14 
(n=26), and non-SS sicca disease controls (n=70). 15 
Results:  16 
All assessments showed a significant difference between the overall SS group and 17 
the disease control group, attributed mainly to the lymphoma subgroups of SS 18 
(p<0.0001 for all parameters). There was a significant correlation (spearman r= 0.7, 19 
p value <0.0001) and 87.3% agreement between USS and the histology focus 20 
scores of 119 patients.  21 
Conclusion:  22 
The results suggest that salivary gland tests including USS can aid in differentiating 23 
between SS and non- SS dry mouth, especially the subgroups of SS with lymphoma 24 








Sjögren’s syndrome (SS) is a heterogeneous multi-systemic disease diagnosed by 2 
certain criteria requiring multiple clinical and laboratory parameters (Shiboski et al., 3 
2017). Xerostomia is one of the main clinical manifestations seen in SS patients. 4 
However, this subjective complaint may not be necessarily reflecting an actual 5 
hyposalivation and loss of salivary gland function (Billings et al., 2016). The loss of 6 
glandular function can be measured via overall or specific glandular flow rates, by 7 
assessing dryness using the clinical oral dryness score (CODS) or implied from 8 
assessing functional glandular structure using the ultrasound severity score (USS).  9 
SS is accompanied by changes in salivary gland structure including focal 10 
lymphocytic infiltration and loss of secretory tissue.   Histological assessment of 11 
gland biopsies is frequently used to demonstrate the loss of normal tissue that may 12 
result in functional loss.  Such histological changes are semi-quantitatively assessed 13 
using a focus score (≥1 lymphocytic aggregate of ≥50 cells per 4 mm2) (Chisholm & 14 
Mason, 1968; Daniels et al., 2011). However, functional impairment might not always 15 
result of tissue loss and patients with normal glands might manifest signs of 16 
functional loss (Colella, Cannavale, Vicidomini, & Itro, 2010). Thus, in this study it 17 
was decided to assess easily applied tests such as flow rates and dry mouth score 18 
while correlating selected measures (USS) with histology.   19 
Due to its well- known detrimental effect on the person’s quality of life (Niklander et 20 
al., 2017) , monitoring xerostomia is of major importance. Indeed, salivary gland 21 
assessments are routinely used as part of the objective diagnostic criteria of SS, 22 
specifically unstimulated whole flow rate (UWSFR) with a cut- off of 0.1 ml/min 23 
(Shiboski et al., 2017).  In addition, individual glandular flow rate tests may 24 
demonstrate the extent of involvement of a particular gland. Even though 25 
submandibular/sublingual flow rates might be useful in the early phases of SS, 26 
parotid flow rate (PFR) might be more informative in patients with longer 27 
(progressive) disease duration according to Pijpe et al., (2007). Scoring systems 28 
have been used to monitor oral dryness and one such system is The Challacombe 29 
scale or Clinical Oral Dryness Score (CODS), which uses a simple numeric system 30 
enabling semi-quantification of the severity of oral dryness over time (Challacombe, 31 
Osailan, & Proctor, 2015). Salivary gland structural changes can also be evaluated 32 
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using ultrasonography, which despite not being part of the diagnostic criteria, has 1 
been suggested as a diagnostic instrument in SS in a number of studies (Astorri et 2 
al., 2016; Jousse-Joulin et al., 2016, Ali et al, 2013 ). A simplified ultrasound scoring 3 
system (USS) was developed (Brown, 2010), based on a system proposed by 4 
Hočevar et al., (2005). USS may be uninformative in early phases of SS, but might 5 
be that more specific in later stages with higher US scores.      6 
This retrospective study has assessed the ability of some easily applied and 7 
repeatable salivary gland parameters to differentiate between SS subgroups and 8 
another non- SS sicca group. SS groups included SS, SS at higher risk of 9 
developing MALT-L and those who had developed MALT-L. As the differentiation 10 
between the more severe groups could allow for treatment at the first signs of cancer 11 
and improve the likelihood of success.  Comparison was made with a disease control 12 
(DCT) group consisting of patients with non- specific sialadenitis, nodal osteoarthritis 13 
& xerostomia (SNOX) (Kassimos et al., 1997), patients with xerostomia and on 14 
polypharmacy therapy and those without a specific diagnosis (not otherwise 15 
specified; NOS).   We hypothesised that measurements of salivary gland 16 
involvement; whole mouth and parotid flow rates, CODS and USS may discriminate 17 
between SS subgroups and other dry mouth patients. A secondary hypothesis was 18 
that USS of major salivary glands reflects salivary gland damage in all glands and 19 
would significantly correlate with minor salivary glands histopathology focus scores 20 












Materials and methods 1 
Study group 2 
The protocol for this study was reviewed and approved by the National Research 3 
Ethics Service (NRES) Committee (11/LO/1121). Patients with symptomatic dry 4 
mouth attending Guy’s and St. Thomas’s Hospital Oral Medicine department (GSTT 5 
NHS Foundation Trust) were included. The series of 244 was divided into 2 groups: 6 
a) Disease control subjects (DCT; n= 70) subgrouped according to their relevant 7 
findings: 8 
1)  Patients who complained of xerostomia and were on polypharmacy 9 
therapy with a reduction of UWSFR as described by Wolff et al. (2017) 10 
(n=25). 11 
2) Patients complaining from  xerostomia  with a negative serology test 12 
for SS while having non-specific sialadenitis on their biopsy results and 13 
confirmed generalised nodal osteoarthritis were diagnosed as SNOX 14 
(n=25) (Kassimos et al., 1997). 15 
3)  Not otherwise specified (NOS; n=20) patients who did not fit any of 16 
the above groups.  17 
b) Overall SS group (n=174) was  subdivided into:  18 
1) Patients who fulfilled the American-European Consensus Group 19 
(AECG) criteria (Vitali et al., 2002) as SS patients (n=118) without risk 20 
factors or the presence of MALT lymphomas (SS-low risk). 21 
2) Patients defined as higher risk of developing MALT-L (n=30) 22 
presenting with at least three of any of the commonly reported risk 23 
factors (e.g. persistent or recurrent parotid enlargement, 24 
cryoglobulinemic vasculitis, raised β2 microglobulin levels, 25 
lymphopenia, hypergammaglobulinemia, hypocomplementemia, high 26 
focus score,  germinal centre in their biopsy and previous lymphoma) 27 
(Nocturne & Mariette, 2015). In order to have more stringent selection 28 
of specified patients who were considered at higher risk of MALT 29 
lymphoma development, a group of at least 3 factors was chosen as 30 
selection criteria.  31 
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3) SS with (MALT-L) patients (n=26). MALT lymphoma was confirmed via 1 
histopathological assessment of biopsies of either parotid glands in 2 
most of the patients or minor salivary glands in 2 patients, while one 3 
patient had submandibular lymphoma. 4 
The mean time for development of lymphoma after the diagnosis of SS was found to 5 
be about 4 years. Treatment had been commenced within the same year of MALT-L 6 
diagnosis and was surgical excision (partial or full) for 13/26 patients (50%) followed 7 
by chemotherapy or radiotherapy in some cases. For the other 13 patients a watch 8 
and wait policy (observation) was adopted for 6 (23%) patients, three patients (13%) 9 
had radiotherapy (4 Gy in two fractions) (low intensity radiation) while three had 10 
chemotherapy (10 mg chlorambucil cycles). One patient had rituximab treatment. 11 
Salivary measurements were recorded after their treatment.  12 
Data collection 13 
Electronic patient records (EPR) and medical notes of patients were initially 14 
examined during the years of 2013 to early 2016. All patients had been or were 15 
currently being followed at clinics. Whole and parotid saliva flow rates, ultrasound 16 
and dry mouth scores (USS and CODS) were recorded for all the patients when 17 
present in the medical notes. In addition, blood tests indicating the increased risk of 18 
developing lymphoma were recorded (e.g. complement level, cryoglobulins, 19 
gammaglobulins and β2 microglobulin levels). Cross-sectional comparisons between 20 
different subgroups were made. A summary of the different diagnostic groups for the 21 
cross-sectional study is shown in Table S1 and a detailed protocol of each test are 22 









Data analysis 1 
The sample size was calculated using independent samples t test. Assuming a 2 
moderate effect size of 0.4, a study with 80% power would require a total sample of 3 
244 (70 for the Disease control group and 174 for the Overall SS group) with an 4 
allocation ratio of 0.4 to test the difference in parameters between the groups at 5% 5 
level of significance. The power calculation for this study was carried out using 6 
Gpower version 3.1.5. For the cross- sectional analysis, comparison between 2 7 
groups (disease controls vs. overall SS groups) was made via Mann–Whitney U 8 
tests then Kruskal-Wallis test followed by Dunn’s post-hoc tests to determine the 9 
differences between the multiple groups (SS subdivisions) for parameters that were 10 
not normally distributed (PFR, UWSFR and USS). CODS were normally distributed 11 
thus one- way ANOVA followed by Scheffe post-hoc test were used for multiple 12 
comparisons and independent sample t- tests for comparing 2 groups (disease 13 
controls vs. all SS groups). Spearman's rank correlation coefficient (Spearman's rho) 14 
was used to determine the associations between flow rates and scores. Cohen’s 15 
kappa coefficient was used to measure the level of agreement between biopsy focus 16 
scores and USS while Spearman's rank correlation coefficient (Spearman's rho) was 17 
used to assess their relationship. Discriminant validity was assessed via Receiver 18 
Operator Characteristic (ROC) curves to determine the ability of USS to differentiate 19 
between SS subgroups and the DCT group. Negative and positive predictive values 20 
as well as odds ratios were calculated from contingency table generated using the 21 
optimal cut-off. The median and quartiles were used as estimates of central 22 
tendency and dispersion of non-parametric data while means and standard error of 23 
mean (SEM) were used to demonstrate the parametric data. The significance level 24 









Clinical parameters outcome 2 
UWSFR 3 
The overall median (Q1-Q3) UWSFR for the SS group as a whole group was 0.04 4 
(0- 0.16) ml/min which was significantly reduced when compared with the disease 5 
control group 0.12 (0.1- 0.24) ml/min (p <0.0001). (Fig.1 (A), (a)). 6 
Subgrouping of SS revealed a reduction of flow rates of the MALT-L higher risk 7 
group 0.01 (0- 0.1) ml/min and MALT-L group 0.002 (0- 0.06) ml/min when compared 8 
with the disease control group (p <0.0001 for both) and the SS-low risk subgroup 9 
0.08 (0- 0.24) ml/min (p=0.039 and 0.049 respectively) (Fig.1 (A), (b)). No significant 10 
difference was detected between the SS-low risk subgroup and disease control 11 
group (Fig.1 (A), (b)). 12 
 13 
Stimulated PFR 14 
The (median (Q1-Q3)) stimulated PFR of the overall SS group (0.14 (0- 0.3)) ml/min 15 
was significantly lower than the disease control group 0.28 (0.16- 0.44) ml/min (p 16 
<0.0001) (Fig.1 (B), (a)). In the SS subgroups, MALT-L higher risk 0.01 (0- 0.25) 17 
ml/min and MALT- L 0 (0-0.13) ml/min were significantly less when compared with 18 
disease control group (p=0.005 and <0.0001 respectively) whereas only the MALT-L 19 
group was reduced compared with the SS-low risk subgroup 0.22 (0- 0.33) ml/min 20 
(p=0.022) Fig.1 (B), (b)). The mean PFR in the SS-low risk subgroup was not 21 
reduced in comparison with the disease control group (Fig.1 (B), (b)). 22 
 23 
USS 24 
The median (Q1-Q3) USS of the overall SS group of 5 (4-7) was significantly greater 25 
than the disease control group 0 (0-0) (p <0.0001) (Fig.1 (C), (a)). 26 
  All SS subgroups showed significantly increased median values when compared 27 
with disease controls (p <0.0001 in all) (Fig.1 (C); SS 5 (3-5), MALT-L higher risk 6.5 28 
(5-8) and MALT-L 7.5 (6-9) (b)).  In addition, both mean values in the MALT-L higher 29 
risk and MALT-L groups were significantly increased when compared with the SS-30 
low risk subgroup (p= 0.001 and p <0.0001 respectively) (Fig.1 (C), (b)). 31 




The mean dry mouth score (CODS) of the overall SS group (mean± SEM) (4.9± 0.2) 2 
was significantly greater than the disease control group (DCT) (3.2± 0.3) (p< 0.0001) 3 
Fig.2 (a). Significantly higher mean USS values in all SS subgroups were observed 4 
compared with (DCT); SS-low risk (4.5± 0.3), MALT-L at higher risk (5.3± 0.4) and 5 
MALT-L (6.5± 0.5) (p=0.013, 0.005 and <0.0001 respectively). Amongst the 6 
subgroups, the mean CODS of the MALT-L group was significantly higher than the 7 
SS-low risk subgroup (p=0.008) (Fig.2 (b)).  All the SS salivary gland disease 8 
measures (clinical parameters) correlated well with each other in the overall series 9 
(n=244), notably UWSFR with stimulated PFR (strong correlation p<0.001) and 10 
CODS. CODS moderately correlated with both flow rates. Ultrasound scores showed 11 
a weak but statistically significant correlation with all the measures as shown in 12 
Table 1. 13 
Association of USS with focus scores 14 
The histopathology focus scores of 119 labial gland biopsies out of the 244 subjects 15 
were available (62 SS and 57 DCT subjects). Of the 62 SS patients, 43 patients 16 
were in the SS-low risk subgroup with a mean score ± SEM of 3.7± 0.04, 11 were 17 
MALT-L higher risk patients with a mean score of 5.2± 0.6 and 8 were MALT-L 18 
patients with a mean score of 6.6± 0.6. The mean focal scores for 57/70 DCT 19 
patients was 0 and their histopathology results indicated either normal gland or non- 20 
specific sialadenitis.  Biopsies were not undertaken for the rest of the controls while 21 
the remaining SS patients fulfilled the criteria for SS but their biopsies had not been 22 
scored. A highly statistically significant positive correlation was noted between the 23 
USS and focus score of the overall group (spearman r= 0.7, n=119, p <0.0001). The 24 
correlation in the overall SS group was also statistically significant (spearman r=0.3, 25 







Measurement of agreement 1 
An ultrasound score of ≥4 was considered positive for SS patients and was used to 2 
sort them accordingly to positive and negative disease groups. The focus score of ≥ 3 
1 per 4 mm2 was considered positive for SS. Cohen's kappa (κ) showed a good 4 
agreement between both methods, κ = 0.748 ± (SEM) 0.061, p < .0001.  The overall 5 
agreement was calculated as 87.3% and the USS results had a positive predictive 6 
value (PPV) of 88.1% and a NPV of 89.6% of the biopsy results; out of the 60 7 
patients with negative biopsy results, 8 were positive for ultrasound while out of the 8 
59 patients with positive biopsy results, 7 were negative for ultrasound. 9 
 10 
Optimal cut- off of ultrasound score 11 
From the optimal cut-off points that were computed based on optimum separation via 12 
the ROC curve, USS ≥4 was selected providing the highest sensitivity of 81.0% 13 
(95% CI: 74.4- 86.6) and specificity of 94.3% specificity (95% CI: 86.0- 98.4).and.  14 
The Area Under the Curve (AUC) was 0.92 (95%CI; 0.89 to 0.96) and p<0.0001 with 15 
a likelihood ratio of 7.54 (Fig.3). The USS cut-off of 4 was used to generate a 2X2 16 
contingency table in order to estimate the PPV, negative predictive value (NPV) and 17 













This study has found that the USS may not only discriminate between SS and non-2 
SS dry mouth patients, but also between SS MALT-L related groups (at higher risk 3 
and with MALT-L) and SS non-MALT-L groups. It was decided to select tests that 4 
can be repeatedly and easily applied and to correlate the selected measures with 5 
histology.  A group of patients with non-specific sialadenitis, primary generalised 6 
nodal osteoarthritis & xerostomia (SNOX)  were enrolled as part of a non-SS sicca 7 
(disease) control group because the disease is often confused with SS and shares 8 
some symptoms including fatigue, dryness complaints and signs as well as  9 
inflammation of the salivary glands (non-specific vs. focal in SS groups). SNOX has 10 
been little tested by other studies since its first description by Kassimos et al., (1997) 11 
and later by Price and Venables, (2002) and  is probably underdiagnosed, thus it 12 
was interesting to follow this disease group further. Regarding the patients at higher 13 
risk of MALT-L, a number of risk factors have been documented from large cohort 14 
studies (Nishishinya et al., 2015; Papageorgiou, Voulgarelis, & Tzioufas, 2015). 15 
However, there is no clear explanation as to why these factors should facilitate 16 
lymphoma development but, it might be that they are features of a more advanced 17 
disease. The presence of Ro/SS-A antibodies is correlated with longevity since onset 18 
of SS, greater damage of the glands and extra-glandular manifestations which can 19 
be one of the predictors of lymphoma development.(Maslinska, Przygodzka, 20 
Kwiatkowska, & Sikorska-Siudek, 2015). Although in this study all of the subjects in 21 
the higher risk of MALT-L and confirmed MALT-L groups were female, there appears 22 
to be no published evidence demonstrating a gender difference probably due to the 23 
predominance of female patients in SS (Nishishinya et al., 2015). One study has 24 
suggested that male-sex was not associated with lymphoma development 25 
(Nishishinya et al., 2015). 26 
 In this study, we took the opportunity of defining a group of patients with a higher 27 
risk of developing maltomas by having at least three risk factors (Nocturne & 28 
Mariette, 2015) and comparing their clinical parameters with low risk SS patients and 29 
those SS who had already developed MALT lymphoma. To our knowledge this is the 30 
first study to report discrimination between subgroups of patients with lymphoma 31 
(MALT-L) or a higher risk of developing MALT-L  from SS non MALT-L using an 32 
ultrasound score, although such an application has previously been suggested  33 
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(Bootsma, Spijkervet, Kroese, & Vissink, 2013). Such discrimination was not found 1 
between both MALT-L related SS groups (at higher risk and with MALT-L). The 2 
median ultrasound scores also showed differences between all groups of SS 3 
patients and disease controls, which included patients with SNOX, a non-specific 4 
salivary gland chronic inflammatory disease accompanied by dry mouth.  Using a 5 
cut-off of USS ≥ 4 yielded 81.03% sensitivity, a specificity of 94.3% and odds ratio of 6 
70.5% when comparing all SS patients with disease controls.  The use of USS as a 7 
diagnostic test has previously been suggested by two systematic reviews, which 8 
reported comparable results. Delli et al., (2015) stated a pooled sensitivity of 69% 9 
(95%CI: 0.67–0.71), specificity of 92% (95%CI: 0.91–0.93), and diagnostic odds ratio 10 
of 33.89 (95%CI: 20.75–55.35) in their  meta- analysis, suggesting that USS could 11 
be efficacious in identifying patients with SS, although the lower sensitivity indicates 12 
a considerable number of false negatives who may be patients at their early stages 13 
of SS. Another systematic review by Jousse-Joulin et al., (2016) included studies 14 
evaluating the usefulness of ultrasound and found a range of sensitivity (45.8 to 15 
91.6%) and specificity (73 to 98.1%).   16 
A highly significant correlation between ultrasound scores and histology focus scores 17 
of all SS subjects was found in the present study (spearman r=0.7, p value <0.0001) 18 
suggesting that lymphocytic infiltration is influencing USS and the latter can be used 19 
at all stages of SS.  It would therefore be appropriate to use ultrasound as a first 20 
measure in SS as suggested previously (Jousse-Joulin et al., 2016). In theory, a 21 
positive result for USS (4 or more) complemented by other tests such as ocular, 22 
serology and salivary flow rates could thus replace the need for performing a labial 23 
gland biopsy as  suggested by Takagi et al. (2014) where USS was reported to be 24 
used as alternative to any  of the 3  criteria of the American College of 25 
Rheumatology (Shiboski et al., 2017).  Recently Astorri et al., (2016) also confirmed 26 
the potential of ultrasound in diagnosing SS, reporting an agreement of 91% (κ=0.82) 27 
with histological focus score and a positive predictive value of 85% and a negative 28 
predicative value of 96%. In our results, the level of agreement was lower showing 29 
87.3% concordance between USS and focus score with a slightly higher (88.1%) 30 
positive predictive value but lower negative predictive value (89.6%).  These levels of 31 
agreement occur even though the focus score in our study analyses minor salivary 32 
glands whilst ultrasound assesses major salivary glands.  The predictive values in 33 
13 
 
the present study were calculated based on confirmed diagnoses and there was a 1 
lower negative predictive value (66%) while the positive predictive value was higher 2 
(97%) than the values calculated in relation to histology results. Some studies have 3 
suggested adding USS to the objective measures which form the criteria for SS 4 
diagnosis since they showed an increased sensitivity of up to 87% while retaining 5 
specificity (Cornec et al., 2013).  However, there is a need firstly to determine if other 6 
conditions such as viral or bacterial infections give a similar ultrasound picture and 7 
secondly develop a consensual scoring system for ultrasound with consistent 8 
procedures and appropriate training in achieving reproducible results (Jousse-Joulin 9 
et al., 2016). Also, we also noted that some patients possibly in earlier stages of SS 10 
with US score of 3 or less were considered as negatives for USS but who satisfied 11 
the ACR criteria having positive histology results and reduced flow rates. 12 
Unsurprisingly there was a significant reduction in the mean UWSFR in the overall 13 
SS group when compared with the disease control group. The reduction is mostly 14 
attributed to the subgroups of MALT-L higher risk and MALT-L, which showed the 15 
greatest reductions. Whole flow rate could not differentiate between SS-low risk 16 
subgroup and the other causes of dryness and this is supported by a number of 17 
studies (Billings et al., 2016; Ohyama et al., 2015; S. M. Osailan, Pramanik, Shirlaw, 18 
Proctor, & Challacombe, 2012; van den Berg, Pijpe, & Vissink, 2007).  There were 19 
similar findings for PFR, which was reduced in the overall SS patients in comparison 20 
to the disease controls and this was mainly attributable to the MALT-L higher risk 21 
and MALT-L subgroups since no differences were found between the SS-low risk 22 
subgroup and disease controls as have been reported previously (Kalk et al., 2001; 23 
Kalk, Vissink, et al., 2002; S. M. Osailan et al., 2012; van den Berg et al., 2007).  The 24 
median value of PFR in the MALT-L group was reduced compared with the SS-low 25 
risk subgroup.  UWSFR and PFR showed a strong correlation (r=0.6, p<0.0001) in 26 
concordance to Kalk et al., (2002) and Vissink et al., (2003) (r=0.75, p<0.001).  27 
However, it appears that parotid gland involvement is more evident in later stages of 28 
SS when there may be little correlation between whole mouth and parotid flow rates.  29 
The reduction of whole saliva has been attributed to the significant decrease in the 30 
submandibular/sublingual flows at early stages (Kalk et al., 2001; Kalk, Vissink, et 31 
al., 2002; Pijpe et al., 2007; van den Berg et al., 2007; Vissink et al., 1993). 32 
14 
 
With regards to CODS, the mean value of the overall SS group was greater than the 1 
disease control group and the mean CODS value in each of the subgroups were also 2 
higher than the disease control group. Values in the MALT-L group was significantly 3 
greater than the SS-low risk subgroup. Osailan et al., (2012) previously reported an 4 
increased CODS of SS patients when compared with SNOX and NOS (Challacombe 5 
et al., 2015).  The significant change seen in the MALT lymphoma group might also 6 
be affected by treatment, whether it was chemotherapy or surgery. Cross-sectional 7 
association identified a strong negative correlation between CODS and salivary flow 8 
rates (either whole or parotid). Other studies have identified similar findings of an 9 
inverse relationship between CODS and salivary flow rates (irrespective of their 10 
diagnosis) (Challacombe et al., 2015; S. Osailan, Pramanik, Shirodaria, 11 
Challacombe, & Proctor, 2011; S. M. Osailan et al., 2012). The results of this study 12 
suggest that SS patients at risk of developing MALT lymphomas have significantly 13 
different values of specific salivary parameters (WFR, PFR, CODS and USS) from 14 
SS and non- SS sicca patients. Longitudinal studies may confirm the combination as 15 
useful markers for assessing lymphoma risk in SS. However, further analyses of the 16 
variations in the parameters (UWSFR, PFR, CODS and USS) assessed in this study 17 
are necessary and the inter- and intra- individual and observer variability should be 18 
considered in order to determine whether the differences observed are the result of 19 













SS patients with or at higher risk of developing MALT lymphomas have significantly 2 
different values of specific salivary parameters (WFR, PFR, CODS and USS) from 3 
SS and non-SS dry mouth patients. USS would be the ideal non-invasive test to 4 
differentiate and monitor SS patients in general (81% sensitivity and 94% specificity) 5 
since USS can be easily repeated and might be used in place of sialography to 6 
reveal structural change in salivary glands. USS showed a good correlation and 7 
agreement with focus scores.  An optimum cut- off ultrasound score of 4 could 8 
differentiate SS from non- SS patients. This can be used to prioritise biopsy for 9 
patients showing evidence of SS in their ultrasound.  Ultrasound scores and CODS 10 
were higher in the two advanced SS groups (at higher risk of MALT-L and confirmed 11 
MALT-L) and can be used to monitor development of MALT-L.    12 
 13 
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Fig. 1. Unstimulated whole mouth salivary flow rates (a), parotid flow rate (b), and ultrasound 1 
score (USS) (c) of different groups n= (244).  2 
(A) SS groups are combined and (B) SS subgroups.  3 
DCT; disease controls which are not otherwise specified (NOS), sialadenitis, nodal 4 
osteoarthritis & xerostomia (SNOX) and patients complaining of xerostomia while on 5 
polypharmacy therapy, SS; Sjögren’s syndrome, MALT-L; mucosa associated lymphoid 6 
tissue lymphoma, SS at risk; SS at higher risk of MALT-L. Data are reported as median ± 7 
(IQR) and expressed as mL/min.  8 
(A) Mann–Whitney U test (B) Kruskal-Wallis test followed by Dunn’s post hoc test. 9 
 10 
 11 
Fig. 2. Clinical oral dryness score (CODS) of different groups n= (244). 12 
(A) SS groups are combined (B) SS subgroups.  13 
DCT; disease controls which are not otherwise specified (NOS), sialadenitis, nodal 14 
osteoarthritis & xerostomia (SNOX) and patients complaining of xerostomia while on 15 
polypharmacy therapy, SS; Sjögren’s syndrome, MALT-L; mucosa associated lymphoid 16 
tissue lymphoma, SS at risk; SS at higher risk of MALT-L. Data are reported as mean ± 17 
(SEM).  18 
(A) Independent t- test (B) One way ANOVA followed by Scheffe post hoc test. 19 
 20 
 21 
Fig. 3. ROC curve of ultrasound score in identifying patients with Sjögren’s syndrome. 22 
Overall SS (n=174) and non-SS (disease controls) (n=70) total (n=244). 23 
  24 
20 
 
Table 1. Spearman correlation of the clinical parameters (whole flow rate, parotid flow rate, 1 




 Table 2. X2 analysis of 244 patients with symptomatic dry mouth 6 
 7 
(Chi square=10.84; p<0.0001)                                       PPV=97.24% (95%CI; 93.12- 98.92)              8 








Spearman's rho X2  




PFR .604** 1 
 
 
USS  -.39** -.37** 1  
CODS -.59**                        -.503**                     .39**                                
 
1
Cut-off (4) Overall Sjögren’s syndrome    Disease controls Total 
USS + (> OR =4) (True positives) 141    (False positives) 4 145 
USS - (<4) (False negatives) 33    (True negatives) 66         99 
Total                174                     70 244 
UWSFR; unstimulated whole saliva flow rate, PFR; parotid flow rate, USS; ultrasound 
score, CODS; clinical oral dryness score. ** p<0.0001. Correlation is significant at the 0.01 
level (2-tailed) 



